Either by genetic intervention or pharmacological inhibition, using Tanespimycin (17-AAG), we partially rescue neuronal function in our models of TDP-43 proteinopathy (Figs 1A, 1C and 1D and S1A–S1C Fig). This evidence concerns the gene TARDBP and proteostasis deficiencies.